Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acutus Medical, Inc.AFIB · Entity 83848 | Director | June 15, 2023 | June 15, 2023 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director · PRESIDENT & CEO | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acutus Medical, Inc.
Report date June 15, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| FORM 4SEC Table I · non-derivative | Direct | 24,347 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 8,400 · Balance 24,347 F1: Common Stock F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. |
| FORM 4SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-15 | Direct | 19,600 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Grant · Acquired 19,600 · Balance 19,600 F3: Stock Options (Right to Buy) F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1: Common Stock |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock
F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.
F3: Stock Options (Right to Buy)
F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director.
TANDEM DIABETES CARE INC
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,260 |
Ending reported balance
After 2026-08-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 5,982 · Balance 158,425 Row 2 · 2026-08-15 · Tax withholding · Disposed 3,044 · Balance 155,381 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Row 3 · 2026-08-15 · Exercise / conversion · Acquired 9,934 · Balance 165,315 Row 4 · 2026-08-15 · Tax withholding · Disposed 5,055 · Balance 160,260 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,947 |
Reported balance
After 2026-08-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-15 · Exercise / conversion · Disposed 5,982 · Balance 17,947 F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 69,537 |
Reported balance
After 2026-08-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-15 · Exercise / conversion · Disposed 9,934 · Balance 69,537 F5: Awarded on May 30, 2025 pursuant to the 2023 Plan. F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
F5: Awarded on May 30, 2025 pursuant to the 2023 Plan.
F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed May 21, 2021 01:38 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 296 | $66.76 | $19,760.96 |
DisclosureSEC source: 0001438133-21-000062 · wf-form4_162156106659761.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 17, 2020 through May 17, 2021. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 12:13 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantStock Options (Right to Buy) · Derivative | 10,882 | $0.00 Strike: $19.06 | $0.00 |
DisclosureSEC source: 0000950103-21-004262 · dp148080_4-sheridan.xml · derivative · entry 2 Sheridan John F · CIK 0001365369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,882 Underlying: Common Stock · 10,882 shares Expires 2031-03-17 F2 · derivative.exercise_date: This option vests over three years from March 17, 2021, with 1/3 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 24 equal monthly installments, subject to continued service through each such vesting date. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 12:13 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantCommon Stock | 3,147 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-004262 · dp148080_4-sheridan.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,547 F1 · shares: Represents shares of Common Stock to be delivered in settlement of a restricted stock unit award upon continued service through the designated vesting event. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001438133-20-000144 · wf-form4_160279331344821.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to fifty percent (50%) of the underlying shares on 06/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F7 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 3,223 | $122.41 | $394,520.34 |
DisclosureSEC source: 0001438133-20-000144 · wf-form4_160279331344821.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 3, 2020. F5 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $122.07 to $122.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 5,380 | $121.78 | $655,192.00 |
DisclosureSEC source: 0001438133-20-000144 · wf-form4_160279331344821.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,979 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 3, 2020. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $121.07 to $122.05. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 6,397 | $120.36 | $769,945.48 |
DisclosureSEC source: 0001438133-20-000144 · wf-form4_160279331344821.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,359 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 3, 2020. F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $120.00 to $120.99. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 15,000 | $18.86 | $282,900.00 |
DisclosureSEC source: 0001438133-20-000144 · wf-form4_160279331344821.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 401 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to fifty percent (50%) of the underlying shares on 06/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 401 | $110.37 | $44,258.37 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 3, 2020. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 401 | $18.86 | $7,562.86 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 9,599 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,401 Underlying: Common Stock · 9,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to fifty percent (50%) of the underlying shares on 06/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 9,599 | $110.00 | $1,055,921.68 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 3, 2020. F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $110.00 to $110.04. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 9,599 | $18.86 | $181,037.14 |
DisclosureSEC source: 0001438133-20-000140 · wf-form4_160037912135722.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 6,653 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,180 Underlying: Common Stock · 6,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 05/17/2018, and the remaining shares vested in thiry-six (36) equal monthly installments thereafter. F4 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 16,920 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/16/2017, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F4 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 7,960 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,960 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to twenty-five percent (25%) of the underlying shares on 04/23/2014, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter. F4 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 1,667 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · derivative · entry 7 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares vested in twelve (12) equal monthly installments thereafter. F4 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 100 | $103.02 | $10,302.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 33,100 | $102.20 | $3,382,929.23 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856 F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $102.00 to $102.73. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 6,653 | $9.00 | $59,877.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 16,920 | $23.00 | $389,160.00 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 7,960 | $11.06 | $88,037.60 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 1,667 | $2.59 | $4,317.53 |
DisclosureSEC source: 0001438133-20-000120 · wf-form4_159658594562461.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| May 27, 2020 Filed May 30, 2020 00:47 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 30,272 | $0.00 Strike: $82.34 | $0.00 |
DisclosureSEC source: 0001438133-20-000075 · wf-form4_159079961836822.xml · derivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,272 Underlying: Common Stock · 30,272 shares Expires not disclosed F1 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F4 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on the one year anniversary of the grant date, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of the 2013 Plan. F5 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| May 27, 2020 Filed May 30, 2020 00:47 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 13,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000075 · wf-form4_159079961836822.xml · derivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,116 Underlying: Common Stock · 13,116 shares Expires not disclosed F1 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F3 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. F3 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:38 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,255 | $16.93 | $21,247.15 |
DisclosureSEC source: 0001438133-20-000061 · wf-form4_158993507883925.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2019 through May 15, 2020. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:35 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001438133-20-000017 · wf-form4_158258008551965.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option shall vest as to fifty percent (50%) of the underlying shares on 12/01/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter. F7 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:35 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 700 | $89.62 | $62,735.96 |
DisclosureSEC source: 0001438133-20-000017 · wf-form4_158258008551965.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2019, as amended on December 16, 2019. F5 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $89.60 to $89.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:35 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 12,842 | $88.38 | $1,134,955.41 |
DisclosureSEC source: 0001438133-20-000017 · wf-form4_158258008551965.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,201 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2019, as amended on December 16, 2019. F4 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $88.01 to $88.90. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:35 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 16,458 | $87.39 | $1,438,195.50 |
DisclosureSEC source: 0001438133-20-000017 · wf-form4_158258008551965.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,043 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2019, as amended on December 16, 2019. F3 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $87.00 to $87.97. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:35 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 30,000 | $2.59 | $77,700.00 |
DisclosureSEC source: 0001438133-20-000017 · wf-form4_158258008551965.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 00:36 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 462 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001438133-19-000025 · wf-form4_157481499716966.xml · derivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,667 Underlying: Common Stock · 462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option shall vest as to fifty percent (50%) of the underlying shares on 12/01/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter. F4 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 00:36 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 462 | $70.00 | $32,340.00 |
DisclosureSEC source: 0001438133-19-000025 · wf-form4_157481499716966.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2019. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 00:36 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 462 | $2.59 | $1,196.58 |
DisclosureSEC source: 0001438133-19-000025 · wf-form4_157481499716966.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 20:20 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 9,538 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-19-048892 · doc4.xml · derivative · entry 3 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,129 Underlying: Common Stock · 9,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter F5 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 20:20 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 9,538 | $70.03 | $667,946.14 |
DisclosureSEC source: 0001209191-19-048892 · doc4.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2019. F3 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.05. The reporting person undertakes to provide the SEC, the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 20:20 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 9,538 | $2.59 | $24,703.42 |
DisclosureSEC source: 0001209191-19-048892 · doc4.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,835 | $16.93 | $31,066.55 |
DisclosureSEC source: 0001209191-19-030989 · doc4.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2018 through May 15, 2019. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock · Derivative | 1,667 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · derivative · entry 7 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 1,667 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Twenty five percent (25%) of the underlying shares subject to the option vested on 05/17/2018, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock · Derivative | 18,333 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 18,333 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 3,800 | $62.53 | $237,614.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 F3 · price: The price reported reflects the weighted average price. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2018, in multiple transactions at prices ranging from $62.51 to $62.62. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 16,200 | $61.91 | $1,002,942.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,466 F2 · price: The price reported reflects the weighted average price. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2018, in multiple transactions at prices ranging from $61.50 to $62.50. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 1,667 | $9.00 | $15,003.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 18,333 | $2.59 | $47,482.47 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:39 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock · Derivative | 105,000 | $0.00 Strike: $48.36 | $0.00 |
DisclosureSEC source: 0001209191-19-014215 · doc4.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F4 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F5 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on 2/25/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter F6 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001209191-19-011505 · doc4.xml · derivative · entry 1 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F2 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 22:55 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-19-005412 · doc4.xml · derivative · entry 3 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 22:55 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 20,000 | $45.26 | $905,178.00 |
DisclosureSEC source: 0001209191-19-005412 · doc4.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 F2 · price: The price reported is the weighted average price. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29,2018, in multiple transactions at prices ranging from $45.00 to $45.81. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 22:55 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 20,000 | $2.59 | $51,800.00 |
DisclosureSEC source: 0001209191-19-005412 · doc4.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · EVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.